Additional Articles

MD Becker Partners has authored or contributed to other articles, journal publications, and abstracts.

Note: access to full text versions may be available by clicking on the story dates below.

November 2010 – “Past Pitfalls and Potential Promise for Pancreatic Cancer” By Michael D. Becker for Oncology Business Review

9/18/2008 – “The Treatment of Palmar-plantar Erythrodysesthesia” By Michael D. Becker for MDNG

6/1/2008 – “Honing In on Chemoresistance Pathways” By Michael D. Becker for GEN (Genetic Engineering & Biotechnology News)

9/1/2007 – “Radiopharmaceuticals Need a Jump-STaRT” By Michael D. Becker for Oncology Business Review

1/26/2012 – “Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies” by Brett Chase of Minyanville

1/5/2012 – “Dendreon reports spike in Provenge sales; shares soar” by Bill Berkrot of Reuters

10/11/2011 – “Nobel prize-winning science should incubate deals” by David Holley of The Deal

10/7/2011 – “Zytiga creeps up on Provenge prostate-cancer drug” by Ransdell Pierson of Reuters

8/23/2011 – “What’s a Cancer Drug Worth?” by Brett Chase of Minyanville

8/22/2011 – “With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers” by Emily Hayes of The Pink Sheet

8/17/2011 – “Daiichi Sankyo is poster company for sector ripe for M&A” by David Holley of The Deal Pipeline

8/4/2011 – “Dendreon plunges as Provenge prospects wither” by by Bill Berkrot of Reuters

8/4/2011 – “Dendreon’s Stock Plunges on Low Provenge Sales” by Brett Chase of Minyanville